STATE STREET CORP - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 41 filers reported holding CTI BIOPHARMA CORP in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q1 2023$52,236,568
-72.8%
12,437,278
-61.1%
0.00%
-50.0%
Q4 2022$192,355,928
+140.5%
32,005,978
+132.9%
0.01%
+20.0%
Q3 2022$79,982,000
+36.0%
13,742,554
+39.5%
0.01%
+25.0%
Q2 2022$58,802,000
+4541.0%
9,849,528
+3530.0%
0.00%
Q1 2022$1,267,000
+139.5%
271,335
+27.2%
0.00%
Q4 2021$529,000
-15.9%
213,3140.0%0.00%
Q3 2021$629,000
+51.9%
213,314
+29.0%
0.00%
Q2 2021$414,000
+567.7%
165,414
+682.0%
0.00%
Q1 2021$62,000
+6.9%
21,152
+17.2%
0.00%
Q4 2020$58,000
+48.7%
18,0520.0%0.00%
Q3 2020$39,000
+85.7%
18,0520.0%0.00%
Q2 2020$21,000
+23.5%
18,0520.0%0.00%
Q1 2020$17,000
-41.4%
18,0520.0%0.00%
Q4 2019$29,000
+93.3%
18,0520.0%0.00%
Q3 2019$15,000
-6.2%
18,0520.0%0.00%
Q2 2019$16,000
-98.3%
18,052
-98.1%
0.00%
Q1 2019$930,000
+37.4%
958,865
+3.9%
0.00%
Q4 2018$677,000
-63.4%
922,844
+7.7%
0.00%
Q3 2018$1,849,000
-55.5%
856,518
+2.5%
0.00%
Q2 2018$4,159,000
+2980.7%
835,478
+2319.6%
0.00%
Q1 2018$135,000
+132.8%
34,529
+60.6%
0.00%
Q4 2017$58,000
+61.1%
21,505
+94.6%
0.00%
Q3 2017$36,000
-2.7%
11,0510.0%0.00%
Q2 2017$37,000
-21.3%
11,0510.0%0.00%
Q1 2017$47,000
+4.4%
11,051
-90.0%
0.00%
Q4 2016$45,000110,5440.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q4 2019
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 3,904,400$3,355,0002.31%
BVF INC/IL 6,929,690$5,955,0000.65%
CAXTON CORP 324,452$279,0000.32%
NEA Management Company, LLC 3,750,000$3,222,0000.23%
Orbimed Advisors 5,000,000$4,297,0000.07%
Fosun International Ltd 459,274$390,0000.03%
Paloma Partners Management Co 229,800$197,0000.00%
OXFORD ASSET MANAGEMENT LLP 127,602$110,0000.00%
LMR Partners LLP 54,931$47,0000.00%
Tower Research Capital LLC (TRC) 17,495$15,0000.00%
View complete list of CTI BIOPHARMA CORP shareholders